This　study　aimed　to　evaluate　the　possibility　that　Spirulina　platensis　crude　polysaccharides　may　ameliorate　the　lipid　and　carbohydrate　metabolism　disorder,　including　obesity,　hyperlipidemia,　hyperglycemia,　hepatic　steatosis,　and　gut　dysbiosis.　The　results　showed　Spirulina　platensis　crude　polysaccharides　could　improve　body　weight,　serum/liver　lipid　and　carbohydrate　indexes,　and　liver　antioxidant　parameters　in　high-sucrose　and　high-fat　diet　(HFD)-fed　rats,　which　were　accompanied　by　regulated　liver　mRNA　expressions　involved　in　lipid　and　carbohydrate　metabolism　disorder.　In　addition,　SPLP　intervention　significantly　decreased　cecal　level　of　propionic　acid　in　HFD-fed　rats.　Notably,　the　SPLP　could　alter　the　relative　abundance　of　Firmicutes,　Bacteroides,　Proteobacteria,　and　Actinobacteria　at　phylum　levels.　Based　on　Spearman＇s　rank　correlation　coefficient,　serum/liver　lipid　and　carbohydrate　profiles　were　found　significantly　positively　correlated　with　genera　Romboutsia,　Allobaculum,　Blautia,　Phascolarctobacterium,　Bifidobacterium,　Coprococcus,　Turicibacter,　Erysipelotrichaceae_unclassified,　Olsenella,　Escherichia/Shigella,　Coprobacillus,　Lachnospiracea　incertae,　and　Lactobacillus,　but　strongly　negatively　correlated　with　genera　Atopostipes,　Flavonifractor,　Porphyromonadaceae_unclassified,　Barnesiella,　Oscillibacter,　Paraprevotella,　Jeotgalicoccus,　Corynebacterium,　Alloprevotella　and　Bacteroides.　It　was　concluded　that　oral　administration　of　SPLP　could　remarkably　ameliorate　the　lipid　and　carbohydrate　metabolism　disorder　and　significantly　modulate　the　intestinal　microbiota　in　HFD-fed　rats.